Skip to main
LPCN

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. has demonstrated a significant advancement in its pipeline with LPCN 1154, an oral formulation of brexanolone, which showcases an impressive efficacy profile featuring a rapid onset of action, a treatment duration of 48 hours, and a remission rate of up to 61% at Day 3 with no adverse events related to sedation reported in clinical trials. The company is on track for a topline readout in the second quarter of 2026, bolstering the likelihood of regulatory approval to 50%, indicating a growing confidence in its product offerings. Despite a modest net loss of $3.2 million, the firm's innovations and potential for future revenue streams from its products present a favorable outlook for investors.

Bears say

Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, indicating ongoing financial challenges as the company continues to invest in its drug development pipeline. The company faces significant risks associated with its lead candidate LPCN 1154, including potential failure in clinical trials, obstacles to obtaining regulatory approval, and challenges regarding commercial success due to factors such as reimbursement and competition. Additionally, the prospect of dilution poses further concerns for shareholders, compounding the negative outlook regarding Lipocine's stock performance.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.